Robert Rushakoff, MD, Mary Sullivan, RN, DNP, ANP-BC, CDE, and other UCSF clinicians are focused on improving diabetes management for both hospitalized patients and patients transitioning both into the hospital and then back to their homes. In a recent journal article, Dr. Rushakoff and his colleagues reported how an online educational module completed by 283 pediatric nurses helped to reduce the hospital's insulin error rate from nearly 15% to less than 2%.
Significant progress has been made in improving the results and clinical applicability of pancreatic islet transplantation as a treatment for type 1 diabetes. UCSF is a member of the Clinical Islet Transplant (CIT) Consortium, an international collaborative effort that is conducting several multicenter trials examining the outcomes of pancreatic islet transplantation in patients with type 1 diabetes.
For many, the Thanksgiving holiday is one of good food, family and friends, and a few days off. In my family, we make sure we stop to reflect on all for which we are thankful. For me, I am grateful for the opportunity to lead an outstanding team of researchers and medical professionals who are all committed to discovering better treatments and, ultimately, a cure for diabetes.
The unique program of the UCSF Diabetes Teaching Center brings together the skills of physicians, nurses, pharmacists and nutritionists to provide individuals with therapies, diabetes education and continuing resources. Thousands of people from around the world have completed workshops at the UCSF Diabetes Teaching Center.
Researchers from the UCSF Center for Vulnerable Populations (CVP) at San Francisco General Hospital continue to impact diabetes prevention and management efforts in countless ways through their important translational research.
A number of new investigational studies in diabetes are being launched by the UCSF Pediatric Diabetes Clinical Research Program under the leadership of Steve Gitelman, MD. Investigational studies are studies that are not approved for use in diabetes by the U.S. Food and Drug Administration.
We are honored that ten outstanding diabetes medical professionals and researchers from UCSF, Harvard Medical School, Harvard School of Public Health, Columbia University School of Medicine, and the San Raffaele Hospital and Scientific Institute, Milan Italy will be making presentations at this day-long symposium, moderated by Center Director Matthias Hebrok, PhD.
Even though the Diabetes Center has already received significant funding from the California Institute of Regenerative Medicine (CIRM) for our stem cell research, it was exciting that our expertise in immune tolerance research was recognized and supported through two awards approved by CIRM’s Governing Board on June 22nd.
In Nature Medicine last June, the Justine K Schreyer Endowed Chair in Diabetes Research, Michael German, MD, reported that he and his team have solved an age-old question in diabetes, “How does the onset of pregnancy enable a woman to double the number of islets in her pancreas?”
Late last week, Diabetes Center Faculty Member and Interim Director of the Diabetes Center Matthias Hebrok, PhD, was appointed by Sam Hawgood, MD, the Dean of the School of Medicine, to serve as Director of the Diabetes Center. Dr. Hebrok, the Hurlbut-Johnson Distinguished Professor in Diabetes Research , is one of the world's foremost experts on pancreatic development.
It has been ten years since Jeffrey Bluestone, PhD, was recruited from the University to Chicago to lead the Diabetes Center at UCSF as the AW and Mary Margaret Clausen Distinguished Professor in Metabolism and Endocrinology. By aggressively recruiting some of the most talented basic researchers in diabetes, and by serving as the driving force behind the Diabetes Center's innovative clinical research program, Dr.
Even though dietary research projects are expensive to conduct, two physician researchers are pooling all of their resources to study the health benefits of following the Paleolithic or hunter-gatherer diet enjoyed by our ancestors.
Thanks to UCSF immunologists including Jeff Bluestone, PhD and Todd Brusko, PhD, a paradigm shift in thinking has occurred regarding the immune system’s role in type 1 diabetes. Previously, the goal was to suppress the immune system so insulin-producing beta cells weren’t destroyed.